DWTX
Dogwood Therapeutics, Inc.
Next earnings Aug 11, 2026 · consensus $-0.14 EPS
Last earnings +6.5% on 2026-05-14
$1.49
▼ -16.29%$1.49▼ -68.76%
over 1Y
L $1.34EODHDH $7.91
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today-16.3%
1W+0.7%
1M-10.8%
3M-29.4%
YTD-64.9%
1Y-68.8%
Hold
Conviction
Horizon
Medium (3–12mo)
Street · 8 analysts
Buy
Conservative balance sheet (liabilities/equity 0.20x).
Return on equity -45.7% · latest
Dogwood Therapeutics, Inc. shows limited reported revenue, and -45.7% ROE.
Supporting the case: conservative balance sheet (liabilities/equity 0.20x).
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$15.6M | -$12.3M | -$5.45M | -$12.2M | -$28.0M |
| Net income | -$16.0M | -$12.2M | -$5.30M | -$12.3M | -$34.3M |
| Diluted EPS | -$1.92 | -$1.11 | -$7.05 | -$12.52 | -$7.13 |
| Net margin | — | — | — | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$43.6M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-68.4%
FCF yield—
Quality & risk
ROIC (est.)-29.5%
Free cash flow—
Total debt—
Net cash$6.52M
Piotroski F-Score1/6
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1647.7%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsRoutine disclosure cadence — no material red flags in recent filings.
Recent filings
all on EDGAR ↗8-KPeriod ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗4Period ending 2026-06-162026-06-17open ↗SCHEDULE 13GFiling2026-05-15open ↗10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-142026-05-14open ↗ARSPeriod ending 2025-12-312026-04-27open ↗DEF 14APeriod ending 2026-06-162026-04-27open ↗PRE 14APeriod ending 2026-06-162026-04-17open ↗8-KPeriod ending 2026-03-262026-03-26open ↗
Frequently asked
- Is Dogwood Therapeutics, Inc. (DWTX) a buy?
- DWTX currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.20x).
- What is Dogwood Therapeutics, Inc.'s quality score?
- DWTX scores 30.390715586681026/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001818844, latest 10-Q filed 2026-05-15) · EODHD · as of 7/3/2026, 11:37:38 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.